基于智能聚合物技术的HCV抗原分散式快速检测:一项前瞻性多国研究
本研究开发了SMART-C侧流抗原检测,在埃及、巴基斯坦和日本的前瞻性多国诊断准确性研究中,以HCV RNA PCR为参考标准,对1353份配对样本检测显示敏感性94.6%、特异性91.3%。在21例接受DAA治疗患者中,SMART-C与PCR病毒清除一致转阴19例,支持其用于分散式HCV检测。
要点
- SMART-C抗原检测敏感性94.6%、特异性91.3%,与PCR一致性高(κ=0.843)。
- 检测下限低于10 IU/mL,接近Cobas® 6800 PCR assay(约10 IU/mL)。
- DAA治疗中SMART-C与PCR病毒下降平行,19/21例与PCR清除一致转阴。
核心结论
- SMART-C抗原检测在高风险临床队列中表现出高诊断性能,支持其用于分散式HCV检测。
研究设计与样本
- 2022-2026年在埃及、巴基斯坦和日本医院及现场开展的多国多中心前瞻性诊断准确性研究。
- 采用盲法检测1353份配对血清/血浆样本,以Cobas® 6800 HCV RNA PCR为参考标准。
- 另前瞻性随访21例启动DAA治疗的患者,评估治疗中及病毒清除后SMART-C性能。
主要发现
- 在1353份配对样本中,SMART-C敏感性94.6%(474/501;95% CI,92.3-96.3),特异性91.3%(778/852;95% CI,89.2-93.0)。
- 准确率92.5%,PPV 86.5%,NPV 96.6%,与PCR一致性高(κ=0.843)。
- SMART-C在DAA治疗中与PCR定义的病毒下降平行,19/21例与PCR清除一致转阴。
关键数值与推荐
- SMART-C分析检测下限低于10 IU/mL,接近Cobas® 6800 PCR assay(约10 IU/mL)。
- 敏感性、特异性、准确率、PPV和NPV按STARD指南计算。
临床怎么用
- SMART-C简单侧流格式适合分散式环境,可能助力WHO丙型肝炎消除目标。
- 可在DAA治疗中用于监测病毒下降和清除。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is an unmet need for a rapid, affordable, and highly sensitive point-of-care HCV antigen test suitable for decentralized settings. We developed SMART-C, a lateral-flow assay integrating a thermo-responsive smart polymer for HCV antigen extraction and enrichment with colloidal gold nanoparticles. We evaluated its diagnostic performance against the Cobas® 6800 HCV RNA PCR assay as the reference standard. METHODS: A multinational, multicentre, prospective diagnostic accuracy study was conducted during 2022-2026 at hospital and field sites in Egypt, Pakistan, and Japan. Paired serum/plasma samples from venous blood were tested blindly using SMART-C and quantitative HCV RNA PCR. Sensitivity, specificity, accuracy, positive predictive value (PPV), and negative predictive value (NPV) were calculated following STARD guidelines. Additionally, 21 patients initiating direct-acting antiviral (DAA) therapy were prospectively followed to assess SMART-C performance during treatment and after viral clearance. RESULTS: Among 1,353 paired samples from a high-risk clinical cohort, SMART-C demonstrated 94.6% sensitivity (474/501; 95% CI, 92.3-96.3) and 91.3% specificity (778/852; 95% CI, 89.2-93.0), with 92.5% accuracy, 86.5% PPV, and 96.6% NPV. Agreement with PCR was high (κ=0.843). SMART-C paralleled PCR-defined viral decline during DAA therapy and became negative concordantly with PCR clearance in 19/21 patients. CONCLUSION: SMART-C achieved an analytical limit of detection below 10 IU/mL, approaching that of the Cobas® 6800 PCR assay (∼10 IU/mL). Its high diagnostic performance and simple lateral-flow format support its potential for decentralized HCV testing and contribution to WHO hepatitis C elimination goals.
引用
- Shiha G, Ebara M, Hassan A, et al. A novel decentralized rapid test for detection of HCV antigens using smart polymer technology: a prospective multinational study. J Infect Dis. 2026. PMID: 42752597. doi:10.1093/infdis/jiag450
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。